205 related articles for article (PubMed ID: 23701393)
1. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease.
Lindsay JO; Chipperfield R; Giles A; Wheeler C; Orchard T;
Aliment Pharmacol Ther; 2013 Jul; 38(1):52-61. PubMed ID: 23701393
[TBL] [Abstract][Full Text] [Related]
2. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence.
Feagan BG; Kozma CM; Slaton TL; Olson WH; Wan GJ
J Med Econ; 2014 Dec; 17(12):872-80. PubMed ID: 25162777
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
[TBL] [Abstract][Full Text] [Related]
6. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.
Miot J; Smith S; Bhimsan N
Int J Clin Pharm; 2016 Aug; 38(4):880-7. PubMed ID: 27118462
[TBL] [Abstract][Full Text] [Related]
7. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
8. Infliximab use in Crohn's disease: impact on health care resources in the UK.
Jewell DP; Satsangi J; Lobo A; Probert C; Forbes A; Ghosh S; Shaffer J; Frenz M; Drummond H; Troy G; Turner S; Younge L; Evans L; Moosa M; Rodgers-Gray B; Buchan S
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1047-52. PubMed ID: 16148549
[TBL] [Abstract][Full Text] [Related]
9. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.
Wu EQ; Mulani PM; Yu AP; Tang J; Pollack PF
Value Health; 2008; 11(5):820-9. PubMed ID: 18489509
[TBL] [Abstract][Full Text] [Related]
10. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Kane SV; Chao J; Mulani PM
Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
[TBL] [Abstract][Full Text] [Related]
11. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
[TBL] [Abstract][Full Text] [Related]
12. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.
Koelewijn C; Schrijvers A; Oldenburg B
Neth J Med; 2006; 64(7):212-8. PubMed ID: 16929082
[No Abstract] [Full Text] [Related]
13. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
[TBL] [Abstract][Full Text] [Related]
14. Infliximab decreases resource use among patients with Crohn's disease.
Rubenstein JH; Chong RY; Cohen RD
J Clin Gastroenterol; 2002 Aug; 35(2):151-6. PubMed ID: 12172361
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
Punekar YS; Sunderland T; Hawkins N; Lindsay J
Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
[TBL] [Abstract][Full Text] [Related]
16. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
17. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
[TBL] [Abstract][Full Text] [Related]
20. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
Carter CT; Waters HC; Smith DB
Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
